AbbVie paid Alector $225 million up front five years ago to begin an R&D partnership on two drugs intended to bring an immunotherapy approach to the treatment of Alzheimer’s disease. One of the drugs has reached Phase 2 testing but the pharmaceutical giant has terminated the alliance on a program in Phase 1.
GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in treating neurological disorders. Alector’s approach addresses the role immune cell dysfunction plays in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The VC firm, started by the former heads of Foundation Medicine and Google Ventures, is raising $350 million for its third fund, according to a filing with the Securities and Exchange Commission.
The "immuno-neurology" company expects to raise $176 million in the offering, which it expects to close on Monday.
The company has a "unique" approach to treating Alzheimer's, CEO Arnon Rosenthal says - taking an immunotherapy approach to neurodegenerative disease.
Immunotherapy startup Alector just raised $32 million to expand its pipeline of immune system-modulating drugs for neurodegenerative disease. The "hypothesis-driven" company has a bold approach to this family of disease, which has few effective therapies.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.